Galaxy Medicare (GML)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 1/1

Key Financials

Strengths

• P/E of 7.01 with PEG of 0.52 offers an inexpensive entry relative to profit growth
• Profit growth of 18.13% and Piotroski F-Score of 7/9 indicate healthy recent financials
• ROCE of 17.72% shows reasonable capital efficiency
• Promoter holding of 72.98% aligns management interests
• Dividend yield of 2.06% provides a modest downside cushion

Concerns

• No book value, ROE, or debt/equity disclosed—cannot assess balance-sheet safety
• Tiny market cap of ₹26 Cr and small profit base create high risk and low institutional interest
• Sales growth of only 8.64% makes the topline unexciting
• No obvious catalyst visible within the ₹15.15–₹20.45 52-week range

AI Analysis

Galaxy Medicare is exactly the sort of small, out-of-favour name that Graham would ask me to look at—but only after checking the numbers underneath. At ₹18.60, the market cap is just ₹26 crore, so this is a microcap. The P/E of 7.01 is cheap, and with profit growing 18.13% against a PEG of 0.52, the price seems to be paying me for growth rather than making me pay for it. Sales growth of 8.64% is more subdued, so I cannot call it a fast grower. Still, the company earns a 17.72% ROCE, which tells me the existing capital is being used reasonably well, and a Piotroski score of 7/9 suggests a healthy recent financial position. The 2.06% dividend gives a small income shield while I wait. What bothers me is what I do not know. There is no disclosed book value, no ROE, and no debt/equity figure. If I cannot see the balance sheet, I cannot judge whether the low P/E is a bargain or a value trap. A microcap with a ₹2 crore quarterly net profit has limited room for error. The promoter holding of 72.98% is strong—it aligns interests—but a high promoter stake in a small company can also mean low free float and volatile trading. The 52-week range of ₹15.15 to ₹20.45 tells me this stock has been cheap for a while, and there is no obvious catalyst. I would not call this a wonderful business in the Buffett sense; it is a cheap, mediocre-growth, small-cap perhaps worth studying. Graham would demand a margin of safety: the low P/E and positive ROCE give some, but missing balance-sheet data denies me the full safety check. I would only invest a tiny amount, if at all, after the company discloses clearer financials.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer